Home / Market News / $ANNX

$ANNX news and market catalysts

The 15 most recent market catalysts affecting $ANNX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 3 high impact 10 bullish 1 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Bullish Impact 75
Annexon Reports Third Quarter 2026 Financial Results and Business Updates
Annexon, Inc. announced its third quarter 2026 financial results, reporting a healthy cash position of $213 million, which is projected to fund operations into 2028. This provides …
Nov 5, 2026 Corporate Catalyst Neutral Impact 75
Annexon Provides Update on Phase III ARCHER II Trial for Geographic Atrophy
Annexon announced a crucial update regarding its Phase III ARCHER II trial for vonaprument, a C1q-targeting treatment for geographic atrophy. The confirmation of a single analysis …
Oct 28, 2026 Corporate Catalyst Neutral Impact 55
Annexon, Inc. Announces Virtual Investor Event for ARCHER II Phase 3 Program
Annexon, Inc. announced a virtual investor event to detail its ARCHER II Phase 3 clinical program. This event is significant as it provides an update on a late-stage clinical trial…
Oct 19, 2026 Corporate Catalyst Bullish Impact 75
Annexon shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $14 to $25.
The significant increase in Annexon's price target from $14 to $25 by HC Wainwright & Co. is a strong positive catalyst for the stock. This indicates that the analyst firm sees sub…
Oct 19, 2026 Corporate Catalyst Bullish Impact 65
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25
HC Wainwright & Co. analyst Ananda Ghosh maintained a 'Buy' rating on Annexon (ANNX) and raised the price target from $14 to $25. This significant increase in the price target, nea…
Sep 30, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15
JP Morgan analyst Anupam Rama maintained an 'Overweight' rating on Annexon (ANNX) and raised the price target from $14 to $15. This action signals continued confidence from a promi…
Sep 24, 2026 Corporate Catalyst Neutral Impact 75
Annexon Announces Presentations On Vonaprument For Geographic Atrophy At Retina Society Meeting; Says Phase 3 Results Expected In Q4 2026
The announcement of presentations at a major medical meeting indicates progress and increased visibility for Annexon's vonaprument. The Q4 2026 Phase 3 results timeline provides a …
Sep 1, 2026 Corporate Catalyst Bullish Impact 65
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
JP Morgan analyst Anupam Rama maintained an 'Overweight' rating on Annexon (ANNX) and raised the price target from $10 to $14. This action signals increased confidence from a promi…
Aug 13, 2026 Corporate Catalyst Bullish Impact 55
Citizens Upgrades Annexon to Market Perform
Citizens analyst Jonathan Wolleben upgraded Annexon (ANNX) from Market Underperform to Market Perform. This change in rating suggests that the analyst's previous concerns about the…
Aug 12, 2026 Corporate Catalyst Bearish Impact 92
Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate
Annexon (ANNX) announced its Q2 earnings, reporting a loss of $(0.28) per share, which fell short of the analyst consensus estimate of $(0.24) by a notable 16.67%. This earnings mi…
Aug 6, 2026 Corporate Catalyst Bullish Impact 85
Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study
Annexon reported early, positive clinical data for tanruprubart in treating Guillain-Barré syndrome (GBS) from its ongoing FORWARD study. This is significant because GBS currently …
Jul 31, 2026 Corporate Catalyst Bullish Impact 65
Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance
Annexon, a biopharmaceutical company, announced a new credit facility agreement with Oxford Finance for up to $200 million. This financing provides Annexon with substantial capital…
Jul 21, 2026 Corporate Catalyst Neutral Impact 65
Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3
Citizens analyst Jonathan Wolleben has initiated coverage on Annexon (ANNX), a biotechnology company, with a 'Market Underperform' rating and a price target of $3. This is a signif…
Jul 15, 2026 Corporate Catalyst Bullish Impact 85
Annexon shares are trading higher after the company announced an oral presentation on the neuroprotective effect of vonaprument at the American Society of Retina Specialists. Also, Needham maintained a Buy rating on the stock and raised its price target from $11 to $25.
The headline indicates a strong positive catalyst for Annexon (ANNX). The oral presentation of positive neuroprotective effects of vonaprument at a major medical conference provide…
Jul 15, 2026 Corporate Catalyst Bullish Impact 65
Needham Maintains Buy on Annexon, Raises Price Target to $25
Needham analyst Joseph Stringer maintained a 'Buy' rating on Annexon (ANNX) and substantially raised the price target from $11 to $25. This significant increase in the price target…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.